AVAX Technologies, Inc. is an immuno-oncology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. It offers biological manufacturing services to biotechnology and pharmaceutical companies. The company was founded by Kenneth E. Kovan on January 12, 1990 and is headquartered in Philadelphia, PA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company